Adeno-associated virus vectors for treatment of glycogen storage disease
The present disclosure describes improved adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease, particularly glycogen storage disease type Ia (GSD-Ia). Described are recombinant nucleic acid molecules, vectors and recombinant AAV that include a G6PC promoter/enhancer, a synthetic intron, a G6PC coding sequence (such as a wild-type or codon-optimized G6PC coding sequence), and stuffer nucleic acid sequence situated between the G6PC promoter/enhancer and the intron, as well as between the intron and the G6PC coding sequence. The recombinant AAVs disclosed herein exhibit highly efficient liver transduction and are capable of correcting metabolic abnormalities in an animal model of GSD-Ia.
1. A recombinant nucleic acid molecule comprising nucleotides 182-4441 of SEQ ID NO: 3 or nucleotides 182-4441 of SEQ ID NO: 1.
2. The recombinant nucleic acid molecule of claim 1 , comprising nucleotides 17-4819 of SEQ ID NO: 3 or nucleotides 17-4819 of SEQ ID NO: 1.
3. The recombinant nucleic acid molecule of claim 1 , comprising the nucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 1.
4. A vector comprising the recombinant nucleic acid molecule of claim 1 .
5. The vector of claim 4 , wherein the vector is an adeno-associated virus (AAV) vector.
6. The vector of claim 5 , wherein the AAV vector is an AAV serotype 8 (AAV8) vector.
7. An isolated host cell comprising the recombinant nucleic acid molecule of claim 1 .
8. A recombinant AAV (rAAV) comprising the recombinant nucleic acid molecule of claim 1 .
9. The rAAV of claim 8 , wherein the rAAV is rAAV8.
10. A composition comprising the rAAV of claim 8 in a pharmaceutically acceptable carrier.
11. The composition of claim 10 formulated for intravenous administration.
12. A method of treating a subject diagnosed with a glycogen storage disease, comprising selecting a subject with glycogen storage disease type Ia (GSD-Ia) and administering to the subject a therapeutically effective amount of the rAAV of claim 8 .
13. The method of claim 12 , wherein the rAAV is administered intravenously.
14. The method of claim 12 , wherein the rAAV is administered at a dose of about 1×10 11 to about 1×10 14 viral particles (vp)/kg.
15. The method of claim 14 , wherein the rAAV is administered at a dose of about 1×10 12 to 8×10 13 vp/kg.
16. The method of claim 14 , wherein the rAAV is administered at a dose of about 1×10 13 to 6×10 13 vp/kg.
17. The method of claim 12 , wherein administering the rAAV comprises administration of a single dose of rAAV.
18. The method of claim 12 , wherein administering the rAAV comprises administration of multiple doses of rAAV.